Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by lscfaon Jan 07, 2021 2:03pm
195 Views
Post# 32243622

RE:TFC-1067 and SGLT2

RE:TFC-1067 and SGLT2Co. stopped using skin lightening descriptor because of trial results....

TFC1067 and 2% hydroquinone produced statistically significant skin lightening after 8 weeks of use, but only hydroquinone lightened the normal skin.


https://onlinelibrary.wiley.com/doi/10.1111/jocd.13771



forhandlaren wrote: I recall that Howard stated R+F product release 15-18 months after the signed deal, check out video interview during summer '19.

That would translate to Q1'21. Considering the ongoing compound production at two different sites it would be possible. Let's hope for the best.

I agree that the company quietly has changed the TFC-1067 from Skin Lightener in the broad sense to a more narrow dark spot lightener. Not sure why.

Seems like the same compound, otherwise I would bet on multiple compounds with different properties/effects.

If different I'd say they just follow the changed sentiment on the market. Don't think it is as politically correct as before to market lighter skin.

I'm actually not very happy about the lightening in order to strive for this cultural ideal, but when bad and dangerous treatments could be replaced with a safe one - and the market would persist anyway - I'm all for it.

The next news seems to be SGLT2 for pets. Does anyone know how the difference in scientific steps/requirements between human och pet meds?


<< Previous
Bullboard Posts
Next >>